Bio-Rad Laboratories Class A
276 hedge funds and large institutions have $4.26B invested in Bio-Rad Laboratories Class A in 2017 Q2 according to their latest regulatory filings, with 36 funds opening new positions, 107 increasing their positions, 94 reducing their positions, and 32 closing their positions.
14% more repeat investments, than reductions
Existing positions increased: 107 | Existing positions reduced: 94
13% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 32
12% more capital invested
Capital invested by funds: $3.8B → $4.26B (+$458M)
7% more call options, than puts
Call options by funds: $1.11M | Put options by funds: $1.04M
1% more funds holding
Funds holding: 274 → 276 (+2)
0% more funds holding in top 10
Funds holding in top 10: 10 → 10 (0)
1.07% less ownership
Funds ownership: 77.87% → 76.8% (-1.1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$109M |
| 2 |
Wells Fargo
San Francisco,
California
|
+$55.1M |
| 3 |
CRM
Cramer Rosenthal McGlynn
Stamford,
Connecticut
|
+$47.6M |
| 4 |
CCM
Clearfield Capital Management
New York
|
+$44.1M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$35.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CM
Corvex Management
New York
|
-$184M |
| 2 |
Millennium Management
New York
|
-$61.6M |
| 3 |
ACM
Atlanta Capital Management
Atlanta,
Georgia
|
-$23.4M |
| 4 |
AI
Ariel Investments
Chicago,
Illinois
|
-$21.8M |
| 5 |
HIM
Hermes Investment Management
London Uk,
United Kingdom
|
-$21.3M |
BIO Hedge Fund Activity: Q2 2017 in Review
276 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Bio-Rad Laboratories Class A (BIO) for Q2 2017, worth a combined $4.26B — up 12% from $3.8B a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new BIO positions and 32 closed out — a net gain of 4 holders — while 107 added to existing stakes and 94 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $109M. The largest seller was Corvex Management, cutting an estimated $184M.
- 276 institutional investors held Bio-Rad Laboratories Class A (BIO) as of Q2 2017, up from 274 in Q1 2017.
- Funds reported $4.26B of Bio-Rad Laboratories Class A stock for Q2 2017, up 12% quarter-over-quarter.
- 36 funds opened new Bio-Rad Laboratories Class A positions in Q2 2017 and 32 closed out, a net change of +4 holders.
- The largest Bio-Rad Laboratories Class A buyer in Q2 2017 was Fidelity Investments, an estimated $109M added.
- The largest Bio-Rad Laboratories Class A seller in Q2 2017 was Corvex Management, an estimated $184M sold.
Based on aggregated 13F filings for Q2 2017.